GlassScriptPhysician profile
Oleksandr Pistun
NPI 1629374533
$12,238.97
in general payments reported to CMS, 2019-2025
44 companies · $5,361 in 2025
The $5,361 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2020: $459 · 2021: $35.86 · 2022: $656 · 2023: $841 · 2024: $2,956 · 2025: $5,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,033 · Travel and Lodging: $2,626 · Education: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.33 |
| Travel and Lodging | $2,625.63 |
| Education | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,473.17 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,222.88 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Pulmonx Corporation | $1,222.50 | 2023-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Glaxosmithkline, LLC. | $755.74 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Insmed, INC. | $419.27 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $346.27 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $327.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.86 | 2019-2024 | Ofev |
| Philips North America LLC | $178.56 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $169.96 | 2019-2020 | |
| Mylan Specialty L.P. | $159.54 | 2019-2024 | Yupelri |
| Genzyme Corporation | $142.91 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $127.93 | 2019-2025 | |
| Electromed, INC. | $121.31 | 2022-2025 | Smartvest |
| Portola Pharmaceuticals, LLC | $119.05 | 2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $106.11 | 2024-2025 | |
| Chiesi USA, INC. | $105.64 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $99.73 | 2019 | |
| Genentech USA, INC. | $84.55 | 2020-2025 | Ocrevus Zunovo, Xolair |
| Inspire Medical Systems, INC. | $76.23 | 2023-2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $75.07 | 2020-2025 | Aralast |
| Pfizer INC. | $53.98 | 2019-2025 | |
| Verona Pharma, INC. | $53.41 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $50.47 | 2024-2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $49.34 | 2024 | Acthar |
| Abbvie INC. | $44.40 | 2023-2025 | |
| Shire North American Group INC | $42.47 | 2019 | |
| Vapotherm INC | $39.96 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.84 | 2019 | |
| Ucb, INC. | $35.80 | 2024 | Briviact |
| Amgen INC. | $33.36 | 2024 | Tezspire |
| Viatris Specialty LLC | $32.75 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $32.38 | 2020-2024 | Xarelto |
| United Therapeutics Corporation | $27.46 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $23.59 | 2023 | Lumryz |
| Covidien LP | $22.91 | 2019 | |
| Grifols USA, LLC | $21.22 | 2023 | Prolastin-C Liquid |
| Sk Life Science, INC. | $19.13 | 2024 | |
| Lilly USA, LLC | $18.24 | 2025 | Zepbound |
| Xeris Pharmaceuticals, INC. | $17.45 | 2024 | Keveyis |
| Inogen, INC. | $15.82 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $15.03 | 2023 | |
| Circassia INC. | $14.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleksandr Pistun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.